By vgreene, 8 January, 2018 Continuously re-eval med regimen and adjust prn to account for pt factors and regimen complexity [E]
By vgreene, 8 January, 2018 Use pt-centered approach to guide choice of agent, considering efficacy, hypoglyc risk, ASCVD hx, impact on wt, potential ADRs, renal effects, route of admin, cost, and pt preference [E]
By vgreene, 8 January, 2018 If established ASCVD and not at target after 3mo, add agent w/ proven cardiac benefits (presently empagliflozin and liraglutide) after considering drug-specific and pt factors [A]; canagliflozin may also be considered to ↓ CV events [C]
By vgreene, 8 January, 2018 Continue metformin if combo tx w/ other agents is used, if tolerated and not contraindicated [A]
By vgreene, 8 January, 2018 Continuously re-eval med regimen and adjust prn to account for pt factors and regimen complexity [E]
By vgreene, 8 January, 2018 If established ASCVD, begin tx w/ lifestyle modification + metformin, and subsequently incorporate agent w/ proven cardiac benefits (presently empagliflozin and liraglutide) after considering drug-specific and pt factors [A]; canagliflozin may also be con
By vgreene, 8 January, 2018 Continuously re-eval med regimen and adjust prn to account for pt factors and regimen complexity [E]
